Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Absence of MHC-II expression by lymph node stromal cells results in autoimmunity.

Dubrot J, Duraes FV, Harlé G, Schlaeppi A, Brighouse D, Madelon N, Göpfert C, Stokar-Regenscheit N, Acha-Orbea H, Reith W, Gannagé M, Hugues S.

Life Sci Alliance. 2018 Dec 17;1(6):e201800164. doi: 10.26508/lsa.201800164. eCollection 2018 Dec.

2.

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.

Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN.

Nature. 2019 Jan;565(7737):43-48. doi: 10.1038/s41586-018-0768-9. Epub 2018 Dec 17.

PMID:
30559380
3.

Dendritic Cell Migration Toward CCL21 Gradient Requires Functional Cx43.

Ruez R, Dubrot J, Zoso A, Bacchetta M, Molica F, Hugues S, Kwak BR, Chanson M.

Front Physiol. 2018 Mar 27;9:288. doi: 10.3389/fphys.2018.00288. eCollection 2018.

4.

Pannexin1 links lymphatic function to lipid metabolism and atherosclerosis.

Molica F, Meens MJ, Dubrot J, Ehrlich A, Roth CL, Morel S, Pelli G, Vinet L, Braunersreuther V, Ratib O, Chanson M, Hugues S, Scemes E, Kwak BR.

Sci Rep. 2017 Oct 20;7(1):13706. doi: 10.1038/s41598-017-14130-4.

5.

Cx47 fine-tunes the handling of serum lipids but is dispensable for lymphatic vascular function.

Meens MJ, Kutkut I, Rochemont V, Dubrot J, Kaladji FR, Sabine A, Lyons O, Hendrikx S, Bernier-Latmani J, Kiefer F, Smith A, Hugues S, Petrova TV, Kwak BR.

PLoS One. 2017 Jul 21;12(7):e0181476. doi: 10.1371/journal.pone.0181476. eCollection 2017.

6.

Shaping of Peripheral T Cell Responses by Lymphatic Endothelial Cells.

Humbert M, Hugues S, Dubrot J.

Front Immunol. 2017 Jan 12;7:684. doi: 10.3389/fimmu.2016.00684. eCollection 2016. Review.

7.

The Heterogeneity of Ly6Chi Monocytes Controls Their Differentiation into iNOS+ Macrophages or Monocyte-Derived Dendritic Cells.

Menezes S, Melandri D, Anselmi G, Perchet T, Loschko J, Dubrot J, Patel R, Gautier EL, Hugues S, Longhi MP, Henry JY, Quezada SA, Lauvau G, Lennon-Duménil AM, Gutiérrez-Martínez E, Bessis A, Gomez-Perdiguero E, Jacome-Galarza CE, Garner H, Geissmann F, Golub R, Nussenzweig MC, Guermonprez P.

Immunity. 2016 Dec 20;45(6):1205-1218. doi: 10.1016/j.immuni.2016.12.001.

8.

IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity.

Lippens C, Duraes FV, Dubrot J, Brighouse D, Lacroix M, Irla M, Aubry-Lachainaye JP, Reith W, Mandl JN, Hugues S.

J Autoimmun. 2016 Dec;75:39-49. doi: 10.1016/j.jaut.2016.07.004. Epub 2016 Jul 26.

9.

Fundamental Roles of the Golgi-Associated Toxoplasma Aspartyl Protease, ASP5, at the Host-Parasite Interface.

Hammoudi PM, Jacot D, Mueller C, Di Cristina M, Dogga SK, Marq JB, Romano J, Tosetti N, Dubrot J, Emre Y, Lunghi M, Coppens I, Yamamoto M, Sojka D, Pino P, Soldati-Favre D.

PLoS Pathog. 2015 Oct 16;11(10):e1005211. doi: 10.1371/journal.ppat.1005211. eCollection 2015 Oct.

10.

Macroautophagy in Endogenous Processing of Self- and Pathogen-Derived Antigens for MHC Class II Presentation.

Duraes FV, Niven J, Dubrot J, Hugues S, Gannagé M.

Front Immunol. 2015 Sep 22;6:459. doi: 10.3389/fimmu.2015.00459. eCollection 2015. Review.

11.

Modes of Antigen Presentation by Lymph Node Stromal Cells and Their Immunological Implications.

Hirosue S, Dubrot J.

Front Immunol. 2015 Sep 8;6:446. doi: 10.3389/fimmu.2015.00446. eCollection 2015. Review.

12.

pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation.

Duraes FV, Lippens C, Steinbach K, Dubrot J, Brighouse D, Bendriss-Vermare N, Issazadeh-Navikas S, Merkler D, Hugues S.

J Autoimmun. 2016 Feb;67:8-18. doi: 10.1016/j.jaut.2015.08.014. Epub 2015 Sep 1.

13.

Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells.

Hepworth MR, Fung TC, Masur SH, Kelsen JR, McConnell FM, Dubrot J, Withers DR, Hugues S, Farrar MA, Reith W, Eberl G, Baldassano RN, Laufer TM, Elson CO, Sonnenberg GF.

Science. 2015 May 29;348(6238):1031-5. doi: 10.1126/science.aaa4812. Epub 2015 Apr 23.

14.

Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12.

Melero I, Quetglas JI, Reboredo M, Dubrot J, Rodriguez-Madoz JR, Mancheño U, Casales E, Riezu-Boj JI, Ruiz-Guillen M, Ochoa MC, Sanmamed MF, Thieblemont N, Smerdou C, Hervas-Stubbs S.

Cancer Res. 2015 Feb 1;75(3):497-507. doi: 10.1158/0008-5472.CAN-13-3356. Epub 2014 Dec 19.

15.

Ag-presenting CpG-activated pDCs prime Th17 cells that induce tumor regression.

Guéry L, Dubrot J, Lippens C, Brighouse D, Malinge P, Irla M, Pot C, Reith W, Waldburger JM, Hugues S.

Cancer Res. 2014 Nov 15;74(22):6430-40. doi: 10.1158/0008-5472.CAN-14-1149. Epub 2014 Sep 24.

16.

Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4⁺ T cell tolerance.

Dubrot J, Duraes FV, Potin L, Capotosti F, Brighouse D, Suter T, LeibundGut-Landmann S, Garbi N, Reith W, Swartz MA, Hugues S.

J Exp Med. 2014 Jun 2;211(6):1153-66. doi: 10.1084/jem.20132000. Epub 2014 May 19.

17.

Innate functions of immunoglobulin M lessen liver gene transfer with helper-dependent adenovirus.

Unzu C, Melero I, Morales-Kastresana A, Sampedro A, Serrano-Mendioroz I, Azpilikueta A, Ochoa MC, Dubrot J, Martínez-Ansó E, Fontanellas A.

PLoS One. 2014 Jan 21;9(1):e85432. doi: 10.1371/journal.pone.0085432. eCollection 2014.

18.

Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy.

Ochoa MC, Fioravanti J, Duitman EH, Medina-Echeverz J, Palazon A, Arina A, Dubrot J, Alfaro C, Morales-Kastresana A, Murillo O, Hervas-Stubbs S, Prieto J, Berraondo P, Melero I.

PLoS One. 2012;7(12):e52370. doi: 10.1371/journal.pone.0052370. Epub 2012 Dec 21.

19.

Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism.

Bustos M, Dubrot J, Martinez-Anso E, Larequi E, Castaño D, Palazon A, Belza I, Sanmamed MF, Perez-Gracia JL, Ortiz de Solorzano C, Alfaro C, Melero I.

Oncoimmunology. 2012 Dec 1;1(9):1527-1536.

20.

Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.

Quetglas JI, Dubrot J, Bezunartea J, Sanmamed MF, Hervas-Stubbs S, Smerdou C, Melero I.

Mol Ther. 2012 Sep;20(9):1664-75. doi: 10.1038/mt.2012.56. Epub 2012 Jun 26.

21.

Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation.

Alfaro C, Suárez N, Martínez-Forero I, Palazón A, Rouzaut A, Solano S, Feijoo E, Gúrpide A, Bolaños E, Erro L, Dubrot J, Hervás-Stubbs S, Gonzalez A, Perez-Gracia JL, Melero I.

PLoS One. 2011 Mar 14;6(3):e17922. doi: 10.1371/journal.pone.0017922.

22.

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.

Palazón A, Teijeira A, Martínez-Forero I, Hervás-Stubbs S, Roncal C, Peñuelas I, Dubrot J, Morales-Kastresana A, Pérez-Gracia JL, Ochoa MC, Ochoa-Callejero L, Martínez A, Luque A, Dinchuk J, Rouzaut A, Jure-Kunkel M, Melero I.

Cancer Res. 2011 Feb 1;71(3):801-11. doi: 10.1158/0008-5472.CAN-10-1733. Epub 2011 Jan 25.

23.

Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells.

Hervas-Stubbs S, Riezu-Boj JI, Gonzalez I, Mancheño U, Dubrot J, Azpilicueta A, Gabari I, Palazon A, Aranguren A, Ruiz J, Prieto J, Larrea E, Melero I.

Eur J Immunol. 2010 Dec;40(12):3389-402. doi: 10.1002/eji.201040664.

24.

Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α.

Rouzaut A, Garasa S, Teijeira A, González I, Martinez-Forero I, Suarez N, Larrea E, Alfaro C, Palazón A, Dubrot J, Hervás-Stubbs S, Melero I.

Eur J Immunol. 2010 Nov;40(11):3054-63. doi: 10.1002/eji.201040523. Epub 2010 Oct 27.

25.

Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo.

Suarez N, Alfaro C, Dubrot J, Palazon A, Bolaños E, Erro L, Hervas-Stubbs S, Martinez-Forero I, Morales-Kastresana A, Martin-Algarra S, Sangro B, Lecanda F, Perez-Gracia JL, Gonzalez A, Melero I.

Int J Cancer. 2011 Jul 15;129(2):374-86. doi: 10.1002/ijc.25681. Epub 2010 Nov 16.

26.

Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells.

Dubrot J, Portero A, Orive G, Hernández RM, Palazón A, Rouzaut A, Perez-Gracia JL, Hervás-Stubbs S, Pedraz JL, Melero I.

Cancer Immunol Immunother. 2010 Nov;59(11):1621-31. doi: 10.1007/s00262-010-0888-z. Epub 2010 Jul 6.

27.

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.

Dubrot J, Milheiro F, Alfaro C, Palazón A, Martinez-Forero I, Perez-Gracia JL, Morales-Kastresana A, Romero-Trevejo JL, Ochoa MC, Hervás-Stubbs S, Prieto J, Jure-Kunkel M, Chen L, Melero I.

Cancer Immunol Immunother. 2010 Aug;59(8):1223-33. doi: 10.1007/s00262-010-0846-9. Epub 2010 Mar 25.

PMID:
20336294
28.

Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.

Dubrot J, Palazón A, Alfaro C, Azpilikueta A, Ochoa MC, Rouzaut A, Martinez-Forero I, Teijeira A, Berraondo P, Le Bon A, Hervás-Stubbs S, Melero I.

Int J Cancer. 2011 Jan 1;128(1):105-18. doi: 10.1002/ijc.25333.

29.

Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates.

Fontanellas A, Hervás-Stubbs S, Mauleón I, Dubrot J, Mancheño U, Collantes M, Sampedro A, Unzu C, Alfaro C, Palazón A, Smerdou C, Benito A, Prieto J, Peñuelas I, Melero I.

Mol Ther. 2010 Apr;18(4):754-65. doi: 10.1038/mt.2009.312. Epub 2010 Jan 19.

30.

Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation.

Martinez-Forero I, Rouzaut A, Palazon A, Dubrot J, Melero I.

Clin Cancer Res. 2009 Nov 15;15(22):6751-7. doi: 10.1158/1078-0432.CCR-09-1225. Epub 2009 Nov 3. Review.

31.

Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo.

Murillo O, Ochoa MC, Arina A, Gabari I, Dubrot J, Hervas-Stubbs S, Melero I.

Gene Ther. 2010 May;17(5):687-9. doi: 10.1038/gt.2009.139. Epub 2009 Oct 29. No abstract available.

PMID:
19865177
32.

Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.

Unzu C, Sampedro A, Mauleón I, Vanrell L, Dubrot J, de Salamanca RE, González-Aseguinolaza G, Melero I, Prieto J, Fontanellas A.

J Hepatol. 2010 Mar;52(3):417-24. doi: 10.1016/j.jhep.2009.09.003. Epub 2009 Sep 23.

33.

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.

Murillo O, Dubrot J, Palazón A, Arina A, Azpilikueta A, Alfaro C, Solano S, Ochoa MC, Berasain C, Gabari I, Pérez-Gracia JL, Berraondo P, Hervás-Stubbs S, Melero I.

Eur J Immunol. 2009 Sep;39(9):2424-36. doi: 10.1002/eji.200838958.

34.

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.

Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, Palazon A, Hervas-Stubbs S, Gurpide A, Lopez-Picazo JM, Grande-Pulido E, Melero I, Perez-Gracia JL.

Br J Cancer. 2009 Apr 7;100(7):1111-9. doi: 10.1038/sj.bjc.6604965. Epub 2009 Mar 10.

35.

Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.

Melero I, Martinez-Forero I, Dubrot J, Suarez N, Palazón A, Chen L.

Clin Cancer Res. 2009 Mar 1;15(5):1507-9. doi: 10.1158/1078-0432.CCR-08-2931. Epub 2009 Feb 24.

36.

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.

Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazón A, Azpilikueta A, Ochoa MC, Alfaro C, Solano S, Pérez-Gracia JL, Oyajobi BO, Melero I.

Clin Cancer Res. 2008 Nov 1;14(21):6895-906. doi: 10.1158/1078-0432.CCR-08-0285.

37.

Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.

Melero I, Murillo O, Dubrot J, Hervás-Stubbs S, Perez-Gracia JL.

Trends Pharmacol Sci. 2008 Aug;29(8):383-90. doi: 10.1016/j.tips.2008.05.005. Epub 2008 Jul 1. Review.

PMID:
18599129
38.

Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells.

Arina A, Murillo O, Dubrot J, Azpilikueta A, Gabari I, Perez-Gracia JL, Alfaro C, Berasain C, Prieto J, Ferrini S, Hervas-Stubbs S, Melero I.

Gene Ther. 2008 Apr;15(7):473-83. doi: 10.1038/gt.2008.4. Epub 2008 Feb 14.

PMID:
18273053
39.

Immunotherapy and immunoescape in colorectal cancer.

Mazzolini G, Murillo O, Atorrasagasti C, Dubrot J, Tirapu I, Rizzo M, Arina A, Alfaro C, Azpilicueta A, Berasain C, Perez-Gracia JL, Gonzalez A, Melero I.

World J Gastroenterol. 2007 Nov 28;13(44):5822-31. Review.

40.

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.

Arina A, Murillo O, Hervás-Stubbs S, Azpilikueta A, Dubrot J, Tirapu I, Huarte E, Alfaro C, Pérez-Gracia JL, González-Aseguinolaza G, Sarobe P, Lasarte JJ, Jamieson A, Prieto J, Raulet DH, Melero I.

Int J Cancer. 2007 Sep 15;121(6):1282-95.

41.

Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.

Arina A, Murillo O, Dubrot J, Azpilikueta A, Alfaro C, Pérez-Gracia JL, Bendandi M, Palencia B, Hervás-Stubbs S, Melero I.

Expert Opin Biol Ther. 2007 May;7(5):599-615. Review.

42.

Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena.

Melero I, Arina A, Murillo O, Dubrot J, Alfaro C, Pérez-Gracia JL, Bendandi M, Hervás-Stubbs S.

Clin Cancer Res. 2006 Apr 15;12(8):2385-9. No abstract available.

Supplemental Content

Loading ...
Support Center